Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 01/12/21 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 01/12/21 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
11 | |
| 12/14/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 12/14/20 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
11 | |
| 12/11/20 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
38 | |
| 12/09/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 12/08/20 | 8-K | Current report filing |
|
3 | |
| 11/18/20 | EFFECT | Notice of Effectiveness |
|
1 | |
| 11/16/20 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 11/16/20 | UPLOAD | SEC-generated letter |
|
1 |
